Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia

ConclusionOnce-weekly semaglutide was considered highly cost-effective versus liraglutide 1.2 mg for the treatment of patients with type 2 diabetes in Estonia.FundingNovo Nordisk A/S.Plain Language SummaryPlain language summary available for this article.

http://link.springer.com/10.1007/s13300-018-0542-x

Source: Diabetes Therapy - December 7, 2018 Category: Endocrinology Source Type: research